Crossmark

YTHDC1 is a therapeutic target for B-cell acute lymphoblastic leukemia by attenuating DNA damage response through the KMT2C-H3K4me1/me3 epigenetic axis

Crossref DOI link: https://doi.org/10.1038/s41375-024-02451-z

Published Online: 2024-11-05

Published Print: 2025-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Xinxin

Zheng, Minhua

Ma, Shoubao

Nie, Fengze

Yin, Zhiqiang

Liang, Yanan

Yan, Xianchun

Wen, Weihong

Yu, Jianhua

Liang, Yingmin

Huang, Siyong

Han, Hua https://orcid.org/0000-0002-1872-9700
License Information

Text and Data Mining valid from 2024-11-05

Version of Record valid from 2024-11-05
More Information

Article History

Received: 1 February 2024

Revised: 20 October 2024

Accepted: 23 October 2024

First Online: 5 November 2024

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below